(Circulation. 1997;95:1497-1504.)
© 1997 American Heart Association, Inc.
Articles |
From the Division of Cardiology (C.D.S., C.T.P., E.S.G., W.J.M., C.H., D.J.M., P.-S.C.) and the Department of Cardiovascular Surgery (R.M.K.), Cedars-Sinai Medical Center, Los Angeles, Calif.
Correspondence to Charles D. Swerdlow, MD, 8635 W Third St, Suite 975 W, Los Angeles, CA 90048. E-mail swerdlow{at}ucla.edu.
Background A patient-specific measure of defibrillation efficacy that requires a minimum number of ventricular fibrillation (VF) episodes would be valuable for programming implantable cardioverter-defibrillators (ICDs). The upper limit of vulnerability (ULV) is the weakest shock strength at or above which VF is not induced when a stimulus is delivered during the vulnerable phase of the cardiac cycle. It correlates with the defibrillation threshold (DFT) and can be determined with a single episode of VF. The objective of this study was to test the hypothesis that ICDs programmed on the basis of the ULV convert spontaneous ICD-detected VF reliably.
Methods and Results We studied 100 consecutive patients at ICD implantation and during follow-up of 20±7 months. At implantation, the ULV and DFT were determined, and the ICD system was tested at a shock strength equal to the ULV+3 J. During follow-up, the strength of the first shock was programmed to the ULV+5 J for arrhythmias detected in the VF zone (cycle length <292±17 ms). We reviewed stored detection intervals and electrograms from spontaneous episodes of ICD-detected VF to determine the success rate for appropriate first shocks. The programmed first-shock strength was 17.5±5.2 J. During follow-up, there were 120 appropriate first shocks in 37 patients. The arrhythmia was rapid monomorphic ventricular tachycardia (VT) in 70% of episodes (31 patients), VF in 11% (13 patients), polymorphic VT in 1%, and unclassified in 17% (15 patients). The first shock was successful in 119 of 120 episodes (99%; 95% CI, 93% to 100%). One unclassified episode required two shocks. No patient had syncope associated with an ICD shock or arrhythmic death.
Conclusions ICD shocks can be programmed on the basis of the ULV, a measurement made in regular rhythm, without a direct measure of defibrillation efficacy.
Key Words: defibrillation heart-assist device upper limit of vulnerability
This article has been cited by other articles:
![]() |
M. M. Gulizia, L. Piraino, M. Scherillo, C. Puntrello, C. Vasco, M. C. Scianaro, F. Mascia, O. Pensabene, S. Giglia, G. Chiaranda, et al. A Randomized Study to Compare Ramp Versus Burst Antitachycardia Pacing Therapies to Treat Fast Ventricular Tachyarrhythmias in Patients With Implantable Cardioverter Defibrillators: The PITAGORA ICD Trial Circ Arrhythm Electrophysiol, April 1, 2009; 2(2): 146 - 153. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Lemke, T. Lawo, M. Zarse, A. Lubinski, U. Kreutzer, J. Mueller, A. Schuchert, S. Mitzenheim, D. Danilovic, T. Deneke, et al. Patient-tailored implantable cardioverter defibrillator testing using the upper limit of vulnerability: the TULIP protocol Europace, August 1, 2008; 10(8): 907 - 913. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Curtis Defibrillator Implantation Without Induction of Ventricular Fibrillation: Good Enough? Circulation, May 8, 2007; 115(18): 2370 - 2372. [Full Text] [PDF] |
||||
![]() |
J. D. Day, R. N. Doshi, P. Belott, U. Birgersdotter-Green, M. Behboodikhah, P. Ott, K. A. Glatter, S. Tobias, H. Frumin, B. K. Lee, et al. Inductionless or Limited Shock Testing Is Possible in Most Patients With Implantable Cardioverter- Defibrillators/Cardiac Resynchronization Therapy Defibrillators: Results of the Multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations) Circulation, May 8, 2007; 115(18): 2382 - 2389. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. W Bourn, M. M Maleckar, B. Rodriguez, and N. A Trayanova Mechanistic enquiry into the effect of increased pacing rate on the upper limit of vulnerability Phil Trans R Soc A, June 15, 2006; 364(1843): 1333 - 1348. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Li, V. Nikolski, D. W. Wallick, I. R. Efimov, and Y. Cheng Mechanisms of enhanced shock-induced arrhythmogenesis in the rabbit heart with healed myocardial infarction Am J Physiol Heart Circ Physiol, September 1, 2005; 289(3): H1054 - H1068. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Swerdlow, K. Shivkumar, and J. Zhang Determination of the Upper Limit of Vulnerability Using Implantable Cardioverter-Defibrillator Electrograms Circulation, June 24, 2003; 107(24): 3028 - 3033. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Wathen, M. O. Sweeney, P. J. DeGroot, A. J. Stark, J. L. Koehler, M. B. Chisner, C. Machado, and W. O. Adkisson Shock Reduction Using Antitachycardia Pacing for Spontaneous Rapid Ventricular Tachycardia in Patients With Coronary Artery Disease Circulation, August 14, 2001; 104(7): 796 - 801. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. D. Swerdlow Implantation of Cardioverter Defibrillators Without Induction of Ventricular Fibrillation Circulation, May 1, 2001; 103(17): 2159 - 2164. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Glatter and L. B. Liem Implantable Cardioverter Defibrillator: Current Progress and Management Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2000; 4(3): 162 - 179. [Abstract] [PDF] |
||||
![]() |
P. N. Schauerte, K. Ziegert, M. Waldmann, F. A. Schondube, F. Birkenhauer, K. Mischke, M. Grossmann, P. Hanrath, and C. Stellbrink Effect of Biphasic Shock Duration on Defibrillation Threshold With Different Electrode Configurations and Phase 2 Capacitances : Prediction by Upper-Limit-of-Vulnerability Determination Circulation, March 23, 1999; 99(11): 1516 - 1522. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Windecker, R. E. Ideker, V. J. Plumb, G. N. Kay, G. P. Walcott, and A. E. Epstein The influence of ventricular fibrillation duration on defibrillation efficacy using biphasic waveforms in humans J. Am. Coll. Cardiol., January 1, 1999; 33(1): 33 - 38. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |